[1] Ferlay J,Shin HR,Bray F,et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
[2] 杨红,李婕,郭嘉,等. TIMP3T 和 mtP53 在非小细胞肺癌中的表达及意义[J]. 中国肺癌杂志,2012,15(4):202-207.
[3] Lotan TL,Gurel B,Sutcliffe S,et al. PTEN protein loss by immunostaining:analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients[J]. Clin Cancer Res,2011,17(20):6563-6573.
[4] Zhang MF,Zhang ZY,Fu J,et al. Correlation between expression of p53,p21/WAF1,and MDM2 proteins and their prognosticsignificance in primary hepatocellular carcinoma[J]. J Transl Med,2009(7):110.
[5] Haier J,Nicolson GL. PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow[J].Oncogene,2002,21(9):1450-1460.
[6] Raftopoulou M,Etienne-Manneville S,Self A,et al. Regulation of cell migration by the C2 domain of the tumor supp ressor PTEN[J]. Science,2004,303(5661):1179-1181.
[7] Baig RM,Mahjabeen I,Sabir M,et al. Genetic changes in the PTEN gene and their association with breast cancer in Pakistan[J]. Asian Pac J Cancer Prev,2011,12(10):2773-2778.
[8] Skrnisdttir I,Seidal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage(FIGO I-II) epithelial ovarian cancer[J]. Int J Gynecol Cancer,2011,21(6):1024-1031.
[9] Heikkinen T,Greco D,Pelttari LM,et al. Variants on the promoter region of PTEN affect breast cancer progression and patient survival[J]. Breast Cancer Res,2011,13(6):R130.
[10] Tserga A,Michalopoulos NV,Levidou G,et al. Association of aberrant DNA methylation with clinicopathological features in breast cancer[J]. Oncol Rep,2012,27(5):1630-1638.
[11] Singh G,Odriozola L,Guan H,et al. Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line[J].BMC Cancer,2011,21(11):490.
[12] Rahman MA,Kyriazanos ID,Ono T,et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients:possible relationship with Cox Ⅱand inducible nit ric oxide synt hase[J]. In J Cancer,2002,100(2):152-157.
[13] Aylon Y,Oren M. Living with p53,dying of p53[J]. Cell,2007,130(4):597-602.
[14] Carmer E,Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death[J]. Cell Cycle,2008,7(3):277-282.
[15] Efeyan A,Serrano M. p53:guardian of the genome and policeman of the oncogenes[J]. Cell Cycle,2007,6(9):1006-1010.
[16] Yang Y,Xia T,Li N,et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma[J]. Protein Cell,2013,4(1):71-81.
[17] Hu TH,Wang CC,Huang CC,et al. Down-regulation of tumor suppressor gene PTEN,overexpression of p53,plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection[J]. Oncol Rep,2007,18(6):1417-1426.
[18] Mayo LD,Donner DB. The PTEN,MDM2,P53 tumor Suppressor oncoprotein net work[J]. Trends in Biochemical Sciences,2002,27(9):462- 467.